Your session is about to expire
← Back to Search
Monoclonal Antibodies
BMS-986322 + Rosuvastatin + Metformin + Methotrexate for Healthy Subjects
Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug, BMS-986322, to see how it works when taken with three other common medications. The study involves healthy participants to ensure clear results. Researchers aim to find out if there are any interactions or side effects when these drugs are taken together.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: Part 3: Methotrexate + BMS-986322 + LeucovorinExperimental Treatment3 Interventions
Group II: Part 2: Metformin + BMS-986322 + GlucoseExperimental Treatment3 Interventions
Group III: Part 1: Rosuvastatin + BMS-986322Experimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Methotrexate
2019
Completed Phase 4
~4400
Leucovorin
2005
Completed Phase 4
~6010
BMS-986322
2022
Completed Phase 2
~430
Rosuvastatin
2019
Completed Phase 4
~3150
Glucose
2017
Completed Phase 4
~850
Metformin
2006
Completed Phase 4
~2430
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,696 Previous Clinical Trials
4,098,995 Total Patients Enrolled